Rapid Dose Therapeutics Corp. (DOSE.CN)
CAD 0.2
(2.63%)
CAD 0.2
(2.63%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.12 Million CAD | 883.28% |
| 2022 | 216.1 Thousand CAD | -40.66% |
| 2021 | 364.18 Thousand CAD | -45.93% |
| 2020 | 673.54 Thousand CAD | -29.78% |
| 2019 | 959.2 Thousand CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.36 Million CAD | 5.4% |
| 2024 Q1 | 2.24 Million CAD | 5.7% |
| 2023 Q4 | 2.12 Million CAD | 6.77% |
| 2023 Q3 | 1.99 Million CAD | 48.16% |
| 2023 Q2 | 1.34 Million CAD | 592.72% |
| 2023 Q1 | 193.9 Thousand CAD | -10.27% |
| 2023 FY | 2.12 Million CAD | 883.28% |
| 2022 Q3 | 312.19 Thousand CAD | -21.32% |
| 2022 Q4 | 216.1 Thousand CAD | -30.78% |
| 2022 FY | 216.1 Thousand CAD | -40.66% |
| 2022 Q1 | 282.91 Thousand CAD | -22.32% |
| 2022 Q2 | 396.77 Thousand CAD | 40.24% |
| 2021 Q1 | 598.5 Thousand CAD | -11.14% |
| 2021 Q2 | 521.95 Thousand CAD | -12.79% |
| 2021 Q3 | 443.85 Thousand CAD | -14.96% |
| 2021 Q4 | 364.18 Thousand CAD | -17.95% |
| 2021 FY | 364.18 Thousand CAD | -45.93% |
| 2020 Q2 | 1.31 Million CAD | 48.24% |
| 2020 Q3 | 747.11 Thousand CAD | -43.37% |
| 2020 Q4 | 673.54 Thousand CAD | -9.85% |
| 2020 FY | 673.54 Thousand CAD | -29.78% |
| 2020 Q1 | 889.91 Thousand CAD | -7.22% |
| 2019 Q4 | 959.2 Thousand CAD | -6.61% |
| 2019 FY | 959.2 Thousand CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 Q3 | 1.02 Million CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | - CAD | -Infinity% |
| Asep Medical Holdings Inc | - CAD | -Infinity% |
| BetterLife Pharma Inc. | 245.23 Thousand CAD | -766.47% |
| BioVaxys Technology Corp. | - CAD | -Infinity% |
| ChitogenX Inc. | 3.27 Million CAD | 35.197% |
| Defence Therapeutics Inc. | 7871.00 CAD | -26896.29% |
| Entheon Biomedical Corp. | - CAD | -Infinity% |
| Gemina Laboratories Ltd. | 205.98 Thousand CAD | -931.584% |
| Glow Lifetech Corp. | - CAD | -Infinity% |
| Lexston Life Sciences Corp. | - CAD | -Infinity% |
| Pharmala Biotech Holdings Inc. | - CAD | -Infinity% |
| Doseology Sciences Inc. | - CAD | -Infinity% |
| MYND Life Sciences Inc. | - CAD | -Infinity% |
| Nova Mentis Life Science Corp. | - CAD | -Infinity% |
| PharmaTher Holdings Ltd. | - CAD | -Infinity% |
| PreveCeutical Medical Inc. | - CAD | -Infinity% |
| Telescope Innovations Corp. | - CAD | -Infinity% |